Product Description
Mechanisms of Action: MAO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Brazil | Chile | China | Colombia | Dominican Republic | Ecuador | India | Indonesia | Ireland | Italy | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Taiwan | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Helicobacter Infections|Communicable Diseases|Gastrointestinal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2400087082 | N/A |
Not yet recruiting |
Helicobacter Infections |
2026-06-30 |
|
ChiCTR2300073347 | N/A |
Not yet recruiting |
Helicobacter Infections |
2024-12-31 |
|
KY20240123-05 | N/A |
Not yet recruiting |
Helicobacter Infections |
2024-12-31 |
|
NCT05718609 | P4 |
Recruiting |
Communicable Diseases|Helicobacter Infections |
2024-03-01 |